NFL Biosciences, a biopharmaceutical company focused on botanical drugs for addiction treatment, has secured a €500,000 non-dilutive loan from Bpifrance. This funding will support the preparation of the Phase 2 clinical trial application for their drug candidate, NFL-102, anticipated in mid-2026.
Amount: $500.0K
